So the antisense or RNAi approach would decrease both intracellular and extracellular protein levels...ALNY claims this is a benefit vs the mAbs, but at this point there is no data to back that up
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com